利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

75 条记录 (耗时 0.076 秒)

    GENES ASSOCIATED WITH PROGRESSION AND RESPONSE IN CHRONIC MYELOID LEUKEMIA AND USES THEREOF
    6.
    发明申请
    GENES ASSOCIATED WITH PROGRESSION AND RESPONSE IN CHRONIC MYELOID LEUKEMIA AND USES THEREOF 审中-公开
    与慢性粒细胞白血病有关的进展与反应的基因及其用途

    公开(公告)号：US20120072124A1

    公开(公告)日：2012-03-22

    申请号：US13207282

    申请日：2011-08-10

    申请人： Jerald P. Radich ,  Hongyue Dai ,  Mao Mao ,  Janell M. Schelter ,  Peter S. Linsley

    发明人： Jerald P. Radich ,  Hongyue Dai ,  Mao Mao ,  Janell M. Schelter ,  Peter S. Linsley

    IPC分类号： G06F19/20 ,  G01N33/50

    CPC分类号： C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/112 ,  C12Q2600/136 ,  C12Q2600/158 ,  Y02A90/26

    摘要： The invention provides molecular markers that are associated with the progression of chronic myeloid leukemia (CML), and methods and computer systems for monitoring the progression of CML in a patient based on measurements of these molecular markers. The present invention also provides CML target genes, and methods and compositions for treating CML patients by modulating the expression or activity of these CML target genes and/or their encoded proteins. The invention also provides genes that are associated with resistance to imatinib mesylate (Gleevec™) treatment in CML patients, and methods and compositions for determining the responsiveness of a CML patient to imatinib mesylate treatment based on measurements of these genes and/or their encoded proteins. The invention also provides methods and compositions for enhancing the effect of Gleevec™ by modulating the expression or activity of these genes and/or their encoded proteins.

    摘要翻译： 本发明提供了与慢性骨髓性白血病（CML）进展相关的分子标记，以及用于基于这些分子标记物的测量来监测患者中CML进展的方法和计算机系统。 本发明还提供CML靶基因，以及通过调节这些CML靶基因和/或其编码蛋白的表达或活性来治疗CML患者的方法和组合物。 本发明还提供了与CML患者中对伊马替尼甲磺酸盐（Gleevec TM）治疗有关的基因，以及基于这些基因和/或其编码蛋白质的测量来确定CML患者对甲磺酸伊马替尼治疗的反应性的方法和组合物 。 本发明还提供了通过调节这些基因和/或其编码的蛋白质的表达或活性来增强Gleevec TM的作用的方法和组合物。

    Genes associated with progression and response in chronic myeloid leukemia and uses thereof
    7.
    发明授权
    Genes associated with progression and response in chronic myeloid leukemia and uses thereof 失效
    与慢性骨髓性白血病中进展和反应相关的基因及其用途

    公开(公告)号：US08014957B2

    公开(公告)日：2011-09-06

    申请号：US11640517

    申请日：2006-12-14

    申请人： Jerald P. Radich ,  Hongyue Dai ,  Mao Mao ,  Janell M. Schelter ,  Peter S. Linsley

    发明人： Jerald P. Radich ,  Hongyue Dai ,  Mao Mao ,  Janell M. Schelter ,  Peter S. Linsley

    IPC分类号： G01N33/48

    CPC分类号： C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/112 ,  C12Q2600/136 ,  C12Q2600/158 ,  Y02A90/26

    摘要： The invention provides molecular markers that are associated with the progression of chronic myeloid leukemia (CML), and methods and computer systems for monitoring the progression of CML in a patient based on measurements of these molecular markers. The present invention also provides CML target genes, and methods and compositions for treating CML patients by modulating the expression or activity of these CML target genes and/or their encoded proteins. The invention also provides genes that are associated with resistance to imatinib mesylate (Gleevec™) treatment in CML patients, and methods and compositions for determining the responsiveness of a CML patient to imatinib mesylate treatment based on measurements of these genes and/or their encoded proteins. The invention also provides methods and compositions for enhancing the effect of Gleevec™ by modulating the expression or activity of these genes and/or their encoded proteins.

    摘要翻译： 本发明提供了与慢性骨髓性白血病（CML）进展相关的分子标记，以及用于基于这些分子标记物的测量来监测患者中CML进展的方法和计算机系统。 本发明还提供CML靶基因，以及通过调节这些CML靶基因和/或其编码蛋白的表达或活性来治疗CML患者的方法和组合物。 本发明还提供了与CML患者中对伊马替尼甲磺酸盐（Gleevec TM）治疗有关的基因，以及基于这些基因和/或其编码蛋白质的测量来确定CML患者对甲磺酸伊马替尼治疗的反应性的方法和组合物 。 本发明还提供了通过调节这些基因和/或其编码的蛋白质的表达或活性来增强Gleevec TM的作用的方法和组合物。

    METHODS AND COMPOSITIONS FOR REGULATING CELL CYCLE PROGRESSION
    8.
    发明申请
    METHODS AND COMPOSITIONS FOR REGULATING CELL CYCLE PROGRESSION 有权
    用于调节细胞周期进程的方法和组合物

    公开(公告)号：US20100035966A1

    公开(公告)日：2010-02-11

    申请号：US12304968

    申请日：2007-06-14

    申请人： Peter S. Linsley ,  Janell Schelter ,  Julja Burchard ,  Lee Lim ,  Miho Kibukawa

    发明人： Peter S. Linsley ,  Janell Schelter ,  Julja Burchard ,  Lee Lim ,  Miho Kibukawa

    IPC分类号： A61K31/7105 ,  C12N5/10 ,  C12Q1/68 ,  C07H21/02

    CPC分类号： C12N15/111 ,  C12N2310/14 ,  C12N2320/12 ,  C12N2330/10 ,  C12N2330/31

    摘要： In one aspect, a method is provided of inhibiting proliferation of a mammalian cell comprising introducing into said cell an effective amount of at least one at least one small interfering RNA agent (iRNA), wherein said iRNA comprises a nucleotide sequence of at least 15 nucleotides, wherein the nucleotide sequence comprises a seed region consisting of nucleotide positions 1 to 12, wherein position 1 represents the 5′ end of the iRNA nucleotide sequence and wherein said seed region comprises a nucleotide sequence of at least six contiguous nucleotides that is complementary to six contiguous nucleotides within positions 1 to 12 of a nucleotide sequence, wherein position 1 represents the 5″end of the nucleotide sequence, wherein the nucleotide sequence is selected from the group consisting of SEQ ID NO: 1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7 and SEQ ID NO:8. In some embodiments, the method comprises introducing at least one iRNA that inhibits the expression of at least one miR-16 responsive gene selected from TABLE 5 into the mammalian cell.

    摘要翻译： 一方面，提供抑制哺乳动物细胞增殖的方法，包括向所述细胞中引入有效量的至少一种至少一种小干扰RNA试剂（iRNA），其中所述iRNA包含至少15个核苷酸的核苷酸序列 ，其中所述核苷酸序列包含由核苷酸位置1至12组成的种子区，其中位置1表示iRNA核苷酸序列的5'末端，并且其中所述种子区包含与六个互补的至少六个连续核苷酸的核苷酸序列 其中位置1代表核苷酸序列的5'末端，其中所述核苷酸序列选自SEQ ID NO：1，SEQ ID NO：2，SEQ ID NO：2 SEQ ID NO：3，SEQ ID NO：4，SEQ ID NO：5，SEQ ID NO：6，SEQ ID NO：7和SEQ ID NO：8。 在一些实施方案中，所述方法包括将至少一种抑制至少一种选自表5的miR-16应答基因的表达的iRNA引入到哺乳动物细胞中。